Barclays raised the firm’s price target on CVS Health (CVS) to $73 from $71 and keeps an Overweight rating on the shares post the Q4 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health: Strong Q4 Performance and Promising 2025 Outlook Justify Buy Rating
- Top Analysts Upgrade CVS Health Stock (CVS) after Upbeat Q4 Results
- CVS Health Reports Revenue Growth Amid Segment Challenges
- CVS Health Corp Reported Earnings. Did it Beat Estimates?
- Leerink upgrades CVS Health to Outperform, sees ‘positively skewed’ reward